David Heredia: New ESMO 2025 Guidelines on Early and Locally Advanced NSCLC
David Heredia, Head of the Oncology Department at Punta Medica, shared on X about a recent paper by A. Zer et al. published on ESMO Journals:
“New ESMO 2025 guidelines on early and locally advanced NSCLC are out!
Clear pathways for staging, biomarker testing (EGFR, ALK, PD-L1), perioperative Tx. Neoadjuvant IO (+/- chemo), adjuvant TKIs and IO all included.”
Title: Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
Authors: A. Zer, M.-J. Ahn, F. Barlesi, L. Bubendorf, D. De Ruysscher, P. Garrido, O. Gautschi, L.E. Hendriks, P.A. Jänne, K.M. Kerr, C. Mascaux, T. Mitsudomi, S. Peters, C. Rolfo, A. Sacher, S. Senan, P. Ugalde, N.B. Leighl.
More posts featuring David Heredia.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023